Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront

Jazz Pharmaceuticals plc

Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.
Regulatory milestones up to $525M; commercial milestones up to $862.5M.
Tiered royalties of 10%-20% on annual net sales in the Territory.
Exclusive rights in U.S., Europe, Japan; Asia/Pacific territories excluded per prior BeiGene license.
Agreement effective Nov 29, 2022 following HSR clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.